Sanofi 과거 수익 실적

과거 기준 확인 0/6

Sanofi의 수입은 연평균 -3.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 14%의 비율로 증가했습니다. 매출은 연평균 6.1%의 비율로 증가해 왔습니다. Sanofi의 자기자본이익률은 6.2%이고 순이익률은 9.3%입니다.

주요 정보

-3.3%

수익 성장률

-3.2%

EPS 성장률

Pharmaceuticals 산업 성장	16.3%
매출 성장률	6.1%
자기자본 수익률	6.2%
순이익	9.3%
다음 실적 업데이트	30 Jan 2025

최근 과거 실적 업데이트

Recent updates

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sep 10

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

수익 및 비용 분석

Sanofi 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ENXTPA:SAN 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	48,445	4,506	10,945	7,147
30 Jun 24	47,080	4,216	10,842	6,958
31 Mar 24	46,288	4,538	10,763	6,884
31 Dec 23	46,033	5,400	10,765	6,728
30 Sep 23	45,699	9,066	10,703	6,679
30 Jun 23	46,045	8,617	10,783	6,752
31 Mar 23	46,199	8,357	10,767	6,780
31 Dec 22	45,389	8,371	10,539	6,706
30 Sep 22	44,348	6,409	10,399	6,468
30 Jun 22	42,039	6,643	10,025	6,176
31 Mar 22	40,342	6,666	9,784	5,914
31 Dec 21	39,175	6,223	9,599	5,692
30 Sep 21	38,496	6,174	9,457	5,622
30 Jun 21	37,546	5,777	9,362	5,501
31 Mar 21	36,939	12,197	9,301	5,455
31 Dec 20	37,369	12,294	9,448	5,530
30 Sep 20	37,650	11,224	9,613	5,699
30 Jun 20	37,692	11,138	9,729	5,738
31 Mar 20	38,234	3,453	9,936	5,973
31 Dec 19	37,631	2,855	9,967	6,020
30 Sep 19	36,940	3,179	9,951	6,010
30 Jun 19	36,763	3,591	9,959	6,111
31 Mar 19	36,264	4,439	9,998	5,999
31 Dec 18	35,677	4,319	9,934	5,894
30 Sep 18	35,316	4,041	9,906	5,680
30 Jun 18	34,985	3,243	9,918	5,560
31 Mar 18	35,428	3,539	9,980	5,443
31 Dec 17	36,221	3,773	10,164	5,472
30 Sep 17	36,400	4,593	10,077	5,445
30 Jun 17	36,315	4,744	10,034	5,325
31 Mar 17	35,677	4,682	9,866	5,246
31 Dec 16	34,696	4,395	9,592	5,172
30 Sep 16	34,349	4,195	9,479	5,099
30 Jun 16	34,115	4,154	9,452	5,191
31 Mar 16	34,569	4,440	9,458	5,158
31 Dec 15	34,861	4,411	9,496	5,082
30 Sep 15	37,201	5,292	10,154	5,195
30 Jun 15	32,910	4,628	8,873	4,745
31 Mar 15	35,074	4,329	9,609	4,884
31 Dec 14	31,999	4,273	8,565	4,667
30 Sep 14	33,484	4,112	8,945	4,719
30 Jun 14	33,134	4,140	8,640	4,755
31 Mar 14	33,074	3,812	8,699	4,752
31 Dec 13	31,291	3,639	8,107	4,605

양질의 수익: SAN 에는 €2.0B 큰 일회성 손실이 있습니다. €2.0B 은 지난 12개월 간의 재무 결과에 30th September, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: SAN 의 현재 순이익 이익률 (9.3%) 작년보다 낮습니다 (19.8%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SAN 의 수입은 지난 5년 동안 매년 3.3% 씩 감소했습니다.

성장 가속화: SAN 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: SAN 은 지난 1년 동안 마이너스 수익 성장( -50.3% )을 기록하여 Pharmaceuticals 업계 평균( -19.9% ).

Sanofi 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기